SAN DIEGO, CA, United States
SAN DIEGO, CA, United States

Time filter

Source Type

Hoffman R.M.,Anticancer, Inc. | Hoffman R.M.,University of California at San Diego
Nature Reviews Cancer | Year: 2015

The majority of human solid tumours do not metastasize when grown subcutaneously in immunocompromised mice; this includes patient-derived xenograft (PDX) models. However, orthotopic implantation of intact tumour tissue can lead to metastasis that mimics that seen in patients. These patient-derived orthotopic xenograft (PDOX) models have a long history and might better recapitulate human tumours than PDX models. © 2015 Macmillan Publishers Limited. All rights reserved.


Patent
Anticancer, Inc. | Date: 2014-01-23

This invention relates to methods of modifying pyridoxal 5 phosphate (PLP) dependent enzymes to extend the serum half-life of the enzyme, extend the in vivo period of methionine depletion in a host, and decrease the immunogenicity of the enzyme. A preferred PLP-dependent enzyme to be modified is a methioninase, preferably a recombinant methioninase (rMETase). The invention further relates to compositions comprising a modified PLP-dependent enzyme and methods of using the same.


Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 224.70K | Year: 2014

DESCRIPTION (provided by applicant): Individualized cancer treatment is an important goal, in particular, for pancreatic cancer, which is the most lethal human cancer. Novel transformative therapeutics are also urgently needed to cure this disease. Our laboratory pioneered the orthotopic growth of patient tumors, including colon cancer (1) and pancreatic cancer (2), in nude-mouse models where the tumors grow and metastasize as they did in the patient. Although there is presently much interest in growth of patient tumors in immunodeficient mouse models to individualize therapy and new names for these models have been coined, such as tumorgraft and xenopatients , the current models are still subcutaneous ectopic xenografts in various types of immunodeficient mice. Such ectopic models do not metastasize and therefore do not sufficiently represent the patient. The present application, takes advantages of the patient-like orthotopic models our laboratory pioneered (1-6) as well as the in vivo imaging techn


A composition, method and kit for performing a two-reagent enzymatic homocysteine assay, wherein a single homocysteinase enzyme and a Schiff-based conjugate of N,N-dibutyl-p-phenyldiamine (DBPDA) with pyridoxal 5-phosphate (PLP) are used to measure total homocysteine in plasma or serum. The assay measures a chromophore reaction product of H_(2)S and the DBPDA released from the Schiff-base conjugate in the presence of a Fe^(+3 )containing compound. The resulting chromophore may be measured absorbance or fluorescence spectrophotometry.


Patent
Anticancer, Inc. | Date: 2013-12-24

An individualized bacterial treatment of cancer is provided. The treatment includes a strain of bacteria modified by in-vivo passage through tumor grafts in experimental animals, where the modified strain exhibits enhanced cancer cell-targeting of a specific malignancy arising in a unique individual to the corresponding parent strain of bacteria. The treatment uses this modified strain for the treatment human solid-tumor malignancies by inoculating an individual with a quantity of the strain; and repeating inoculations at periodic intervals where repeated inoculations tend to progressively eliminate the solid tumor malignancy in the individual.


Patent
Anticancer, Inc. | Date: 2013-12-24

A portable digital imaging system for fluorescence-guided surgery is provided. The system includes a portable probe comprising a light source, a fluorescence detector, a digital signal output, a memory and a processor. The system also includes a computer in communication with the portable probe and a display. The portable probe excites a fluorescent label-containing tissue within a surgical field in response to the light source of the portable probe illuminating the fluorescent label-containing tissue. The computer displays a real-time image visualization of the surgical field on the display in response to the computer in communication with the display receiving and processing a digital signal from the digital signal output of the portable probe.


A composition, method and kit for performing a two-reagent enzymatic homocysteine assay, wherein a single homocysteinase enzyme and a Schiff-based conjugate of N,N-dibutyl-p-phenyldiamine (DBPDA) with pyridoxal 5-phosphate (PLP) are used to measure total homocysteine in plasma or serum. The assay measures a chromophore reaction product of H_(2)S and the DBPDA released from the Schiff-base conjugate in the presence of a Fe^(+3 )containing compound. The resulting chromophore may be measured absorbance or fluorescence spectrophotometry.


Patent
Anticancer, Inc. | Date: 2016-03-03

An individualized bacterial treatment of cancer is provided. The treatment includes a strain of bacteria modified by in-vivo passage through tumor grafts in experimental animals, where the modified strain exhibits enhanced cancer cell-targeting of a specific malignancy arising in a unique individual to the corresponding parent strain of bacteria. The treatment uses this modified strain for the treatment human solid-tumor malignancies by inoculating an individual with a quantity of the strain; and repeating inoculations at periodic intervals where repeated inoculations tend to progressively eliminate the solid tumor malignancy in the individual.


The present invention relates to highly conjugated proteins and methods for making such proteins. In particular, the present invention relates to methods for linking additional sites to a protein for conjugation with activated polyethylene glycol (PEG) linkers, without denaturing the protein. The invention also relates to highly conjugated proteins with decreased immunogenicity and increased circulating half-life.


Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 224.70K | Year: 2014

DESCRIPTION (provided by applicant): Nestin-expressing stem cells of the hair follicle, discovered by our laboratory (Proc Natl Acad Sci USA 2003; 100:9658-61[1]), have been shown by our laboratory to be able to form neurons and other non-follicle cell types (Proc Natl Acad Sci USA 2005; 102:5530-4 [2]). Our laboratory has shown that the nestin-expressing stem cells from the hair follicle can effect repair of the peripheral nerve (Proc Natl Acad Sci USA 2005;102:17734-8 [3]) and spinal cord injury (Cell Cycle 2008; 7:1865-9 [4] and Cell Cycle 10, 830-839, 2011 [5]). Transgenic mice, in which the nestin promoter drives GFP (ND-GFP), were used to characterize the nestin-expressing hair follicle. The cells have very long processes extending from them as shown by confocal microscopy and differentiate into neuronal cells at high frequency as well as into multiple other non-hair follicle cells in vitro. The hair follicle sem cells differentiate into neuronal and glial cells after transplantation to the injured

Loading Anticancer, Inc. collaborators
Loading Anticancer, Inc. collaborators